November 5, 2020

Hemp Banking, CBD Banking, and Cannabis Banking: What’s The Difference?

Hemp and cannabis are technically the same plant, but in the eyes of the law, they couldn’t be more different.
November 4, 2020

When will New Jersey launch its adult use market?

Cannabis won big in the 2020 election, but sales in New Jersey will not commence overnight. Fincann expects a 2022 launch. Here's why.
July 24, 2020

How cannabis and hemp CBD differ from a regulatory perspective

For quite a long time and still even today, the end of federal cannabis prohibition has stood as a before and after milestone in the industry. Conventional wisdom has been for industry enterprises to tailor their major shareholder liquidity event for the year following prohibition’s end, which could happen as soon as the first half of 2021. The ‘C-level’ talk at trade conferences has been that of tailoring one’s company to be optimally attractive to specific categories of potential buyers […]
July 24, 2020

Fincann Submits Testimony to House Subcommittee Hearing on Cannabis Banking

Cannabis banking is not about the pros and cons of legalization, potential medical applications, and the myriad challenges faced by an industry struggling to transition from the black market to mainstream acceptance. The most critical and essential issue arising from the lack of banking for the cannabis and hemp industries is actually one of a community safety crisis and not one of the albeit considerable inconveniences and expenses plaguing the industry. The crisis is real, it is severe and it […]
July 24, 2020

Marijuana Banking: Front Line Perspectives for Anti Money Laundering Professionals

It is understandable and reasonable for many folks especially in the conservative mainstream to remain skeptical of recent claims of medical efficacy and harmless non-consequential recreational use of cannabis aka marijuana given decades of pervasive messaging to the contrary. However it is vital for today’s AML and banking professionals to learn the real truth to take timely advantage of opportunity as well as to ‘nip in the bud’ a looming and severe danger both to our communities and our financial […]
July 7, 2020

What the revocation of the Cole Memo means for cannabis banking

Since it remains undisputedly illegal under Federal law, the state-licensed legal marijuana industry currently primarily operates under a presumption of prosecutorial forbearance and perceived rather than actual risk. The Cole Memo is a ‘feel-good’ U.S. Department of Justice guidance that does not actually restrain local U.S. Attorneys General from enforcement, but sets department priorities with regard to marijuana, such as sales to minors or diversion of product out of state. The Rohrbacher-Blumenauer budget amendment, which prohibits use of federal funds […]
April 22, 2019

Congress Weighs New Banking Laws That Could Light Up The Pot Business

[FINCANN CEO Nathaniel] Gurien [believes that] the law won’t dispel the stigma that the conservative-leaning, risk-minded boards of many financial institutions have toward the topic of marijuana. The only measure that could prompt such a shift in thinking, he says, is “de-scheduling cannabis as a Schedule I drug.”
April 22, 2019

Hemp Companies Left Looking For Bank Alternatives

“This was the first time the CBD and hemp industry could look forward to stable merchant processing services, and (Elavon’s) decision to exit means we could go back to some of the back door, tortured, overpriced solutions that the industry had been laboring under.”
January 22, 2019

Cannabis Cash Concerns

The [banking] issue stems from reluctance on the part of financial institutions to work with businesses related to marijuana sales in any way—even when those businesses are located in states that have legalized cannabis.
November 20, 2018

Understanding the Business of Medical Marijuana

Medical marijuana allows Ajay Suman, MD’s cancer patients a safer alternative to opioids for chronic pain. It can be an effective treatment for his terminally ill patients, says Suman, a New York-based anesthesiologist and a professor of anesthesiology and pain medicine at Weill Cornell Medicine, who is qualified to evaluate patients in New York State who want to use marijuana for medical reasons.
Call us : (212) 724-7777